SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

March 31, 2023

Conditions

Breast Cancer

Interventions

DRUG

SHR6390+anatrozole

SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.

Trial Locations (1)

TianJin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT04836520 - SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. | Biotech Hunter | Biotech Hunter